Why Generate Biomedicines, Inc.’s (GENB) Stock Is Down 5.52%
As of Friday, August 28, Generate Biomedicines, Inc.’s GENB share price has dipped by 5.52%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.
Commentary & Analysis
Why Generate Biomedicines, Inc.’s (GENB) Stock Is Up 6.44%
As of Thursday, August 27, Generate Biomedicines, Inc.’s GENB share price has surged by 6.44%, which has investors questioning if this is right time to sell.Michael Rose
Why Generate Biomedicines, Inc.’s (GENB) Stock Is Down 14.06%
As of Wednesday, August 26, Generate Biomedicines, Inc.’s GENB share price has dipped by 14.06%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Generate Biomedicines, Inc.’s (GENB) Stock Is Down 16.78%
As of Wednesday, August 26, Generate Biomedicines, Inc.’s GENB share price has dipped by 16.78%, which has investors questioning if this is right time to buy.Omar Beirat
Why Generate Biomedicines, Inc.’s (GENB) Stock Is Up 15.69%
As of Tuesday, August 25, Generate Biomedicines, Inc.’s GENB share price has surged by 15.69%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | GENB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,053.6 | $270.6 | 54% |
|
| Shares Out (Mil) | 128.2 | 54.4 | 67% |
|
| Institutional Ownership | 87.7% | 92.9% | 55% |
|
| Float (Mil) | 60.4 | 41.4 | 51% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 1,063 | 481 | 73% |
|
| Price Change (52-week) |
na | 55.6% | na |
|
| Growth | GENB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.545) | ($2.300) | ($2.280) | |
| Month Ago EPS | ($0.580) | ($2.353) | ($2.280) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 1 | 2 | |
| Three Months Ago EPS | ($0.540) | ($2.240) | ($2.065) | |
| Year/Year Chg | 4.0% | (53.8%) | (70.0%) | |
| Financials | GENB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $27 | $37 | 15% |
|
| Net Income (TTM) (Mil) | ($238) | ($43) | 6% |
|
| EPS (TTM) | ($3.276) | ($1.500) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($237) | ($31) | 3% |
|
| Net Cash Flow (TTM) (Mil) | ($10) | $2 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $49 | $4 | 39% |
|
| Enterprise Value (Q1) (Mil) | $1,613 | $179 | 46% |
|
| Valuation | GENB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.49 | 2.63 | 76% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | GENB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (807.3%) | 68.2% | 0% |
|
| Net Margin | (897.7%) | (73.0%) | 0% |
|
| ROA | (84.7%) | (47.9%) | 7% |
|
| ROE | (104.3%) | (55.0%) | 9% |
|
| Liabilities to Assets | 18.8% | 29.4% | 12% |
|
| F-Score | 1 | 3 | na |
|
Generate Biomedicines, Inc. did not pass any screens on 9/14/2026.
